Sign in
Taking peopleNo phase

Lacosamide given by vein for sudden trigeminal neuralgia pain in emergency care

Looks at lacosamide for sudden trigeminal neuralgia pain in adults seen in emergency departments.

Key facts

Who runs it
Hospital Universitari de Bellvitge
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia
Status
Recruiting
People taking part
20 people, planned
Started
21 Apr 2025
Expected to end
Dec 2027
Type of study
Observational
Treatments tested
  • Lacosamide
Record updated
15 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with trigeminal neuralgia who come to the emergency department of Hospital de Bellvitge with a sudden worsening of pain. Their doctor must have prescribed intravenous lacosamide for the pain.

Age
Over 18 years.
Sex
All sexes can join.
Disease stage
Classical or idiopathic trigeminal neuralgia, diagnosed by the ICHD-3 criteria, with an acute pain flare.
Earlier treatment
The treating doctor must have prescribed intravenous lacosamide for the pain flare.

Main reasons for not taking part

  • People who cannot take lacosamide, such as after a past allergic reaction to it
  • People with a known atrioventricular block (a heart rhythm problem)
  • A mental or psychiatric illness that makes it hard to understand and sign the consent form
  • A language barrier
  • Lack of cooperation

The registry criteria, word for word

Show all 8 criteriaShow less

Who can take part

  • Diagnosis of classical or idiopathic trigeminal neuralgia according to the criteria of the International Classification of Headache Disorders (ICHD-3)
  • Age over 18 years
  • Signed informed consent

Who cannot take part

  • Contraindication for treatment with lacosamide (previous hypersensitivity reaction, known atrioventricular block)
  • Mental or psychiatric illness that interferes with the ability to understand and sign the informed consent
  • Language barrier
  • Lack of cooperation

Other criteria

  • All patients diagnosed with trigeminal neuralgia who present to the emergency department of Hospital de Bellvitge for an acute pain exacerbation and are prescribed intravenous lacosamide as symptomatic pain treatment, according to the treating physician's discretion, will be considered for inclusion

This trial is currently available in Spain.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective observational study evaluates the effectiveness and safety of intravenous lacosamide as a rescue treatment for acute pain in patients presenting to the emergency department with trigeminal neuralgia

Treatments tested

  • Lacosamide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intravenous Lacosamide for the Treatment of Acute Pain in Trigeminal Neuralgia: A Prospective Observational Study
Plain-language title
Lacosamide given by vein for sudden trigeminal neuralgia pain in emergency careGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
15 September 2026